- Jul 26, 2023
Digital pathology is the latest technological innovation in the healthcare used to examine and analyze tissue samples. It is a rapidly growing medical imaging process that is transforming how pathologists work. Digital pathology allows pathologists to view high-resolution images of tissue samples on a computer screen rather than having to look at them through a microscope. These latest trends in the medical device industry have many benefits, including improved accuracy and efficiency in diagnosis and the ability to share images and collaborate with other pathologists remotely. Pathologists can access and analyze samples from worldwide using digitized imaging, leading to faster and more precise diagnoses.
According to Allied Market Research, the U.S.A. dominated the digital pathology market in 2020 and is expected to continue to do so during the forecast period, i.e., until 2030. It is because of the rise in cancer cases, the availability of leading healthcare service providers, the ultra-modern healthcare sector, and the presence of new innovative digital pathology systems in the country. The U.S. digital pathology market is expected to grow at a CAGR of approximately 9.3% from 2021 to 2030.
What Factors Contributing to the Boom of Digital Pathology in the U.S.A.?
According to Forbes, the advent of the Covid-19 pandemic saw significant demand for remote work capability across every sector & industry, and pathology was no different. Thus, finding digital solutions for every medical facet becomes the need of the hour. The COVID crisis also helped boost innovation in pathology, ultimately paving the way for the digital pathology of the tissue imaging process.
On this front, Allied Market Research says that the rise in population and rapid technological advancements in the digital pathology segment are the factors that have fueled the growth of the digital pathology market in the U.S.A.
Also, the increasing efficiency of digital pathology systems, ease of virtual transportation of slides, and efficient cost of digital pathology products are the key factors augmenting the market growth, according to Stratview Research.
Further, favorable government initiatives in the U.S. and ease of reimbursement policies drive the market growth for digital pathology. It must be noted that currently, the U.S.A. holds a 36% global market share in the digital pathology market, according to Future Market Insights.
Other factors contributing to the growth of digital pathology in the U.S.A. include new C.P.T. codes, single-solution systems, and A.I. development.
Future of Digital Pathology in the U.S:
Digital Pathology facilitates pathologists to engage, assess, and collaborate rapidly and remotely, with clarity and consistency, thus enhancing efficiency and productivity. The future of digital pathology could ultimately encompass improved translational research, computer-aided diagnosis (CAD), and the formation of personalized medical care systems. Adoption is likely to go up with the approval of digital pathology solutions for primary diagnosis in the United States. However, the absence of interoperability among existing healthcare systems and workflow platforms might hinder growth.
Five Key Digital Pathology Companies Operating in the U.S.A.:
There are several digital pathology companies operating in the U.S.A. and of all below we have enlisted 5 best in the business. Without any further delay, let’s continue with our list of leading digital pathology companies.
PathAI:
Founded in 2016, this company is renowned for delivering AI-based medical tools and has been accorded ISO 13485 and ISO 27001 certifications for its superior quality products. This company is located at Boston, Massachusetts and today, PathAI is a leading provider of AI-powered research tools and services for pathology in the country and has developed an indigenous machine-learning-based tool named ‘AISight Dx’ to analyze digital pathology images, which can help pathologists to identify cancer cells and other abnormalities more accurately. Also, PathAI’s platform is presently being used by leading academic medical centers and pharmaceutical companies around the world.
Proscia:
Located in Philadelphia, United States, Proscia is a leading pathology health-tech platform formed in July 2014, and today, it is accelerating research and delivering better outcomes globally with its numerous indigenously built AI applications. Currently, the company’s flagship digital pathology product – Concentriq, a cloud-based platform that allows pathologists to view, analyze, and share digital pathology images, is overhauling the way pathology is performed. Concentriq also integrates with remote clinical systems, making accessing customer data from distant sources easy for pathologists.
Aiforia:
With a mission to provide data-driven healthcare facilities, Aiforia was founded in 2013 and has its head office at Broadway, Cambridge, United States. Since then, it has grown in leaps and bounds, and today, it is a prominent global player in delivering AI-powered image analysis. Currently, this USA-based digital pathology company is available in more than 50 countries and is assisting pathologists, medical scientists, and researchers worldwide. The company’s cloud-based AI pathology software can be used to analyze digital pathology images for various purposes, including cancer detection and prognosis, and is also helpful in treatment planning.
Indica Labs:
Headquartered in Albuquerque, New Mexico, USA, Indica Labs came into being in 2011, and today, it is amongst the top global AI-powered digital pathology tech companies. The company has developed a microenvironment system named – Halo, which provides bio-statistical services to identify prognostic and predictive tumour features. The company has a mission to provide solutions to streamline image analysis workflow for digital pathology. Today, many top pharma companies use cloud-based software solutions powered by AI for image analysis and bioinformatics services. The two most renowned digital pathology tools by Indica Labs are HALO and HALO AI, and both are used for quick, quantitative evaluation of medical images.
DeepBio:
Created in October 2015, DeepBio has a mission to empower clinics to harness the unimaginable power of AI and aims to deliver the highest level of accuracy in digital pathology through its indigenously developed AI-powered software. The company has revolutionized cancer diagnosis by combining cutting-edge AI algorithms with digital pathology to empower pathologists and streamline existing workflows. Initially, the company was formed in Seoul, South Korea, but it has grown immensely and is now available in the United States. Out of many AI-based pathology solutions, its DeepDx® Prostate is the most renowned AI solution for prostate biopsy tissue image analysis.
Wrapping Up:
Digital Pathology is a rapidly growing medical innovation that has the potential to revolutionize the way pathology is practiced comprehensively. The benefits of digital pathology are numerous, and the future of it is very promising. Also, its development is essential for early detection and diagnosis of life-threatening diseases such as cancer, and the same can be a boon for such customers.
